

Substitute for form 1449A/PTO & 1449B/PTO		Complete if Known	
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/531900
		Filing Date	April 21, 2005
		First Named Inventor	Francois Schutze et al.
		Examiner Name	SPIVACK
		Attorney Docket Number	032013-120
Sheet	1 of 2		

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS					
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract
PS	02/072070	A1	WO	09-19-2002						
PS	01/28558	A1	WO	04-26-2001						
PS	99/59544	A2	WO	11-25-1999						
PS	00/50037	A1	WO	08-31-2000						
PS	98/16228	A1	WO	04-23-1998						

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
PS	Anonymous, "Tenatoprazole: benatoprazole, TU 199," DRUGS IN R&D, 3(4); pp. 276-277, 2002.
PS	UCHIYAMA et al., "The Long-lasting Effect of TU-199, a Novel H ⁺ ,K ⁺ -ATPase Inhibitor, on Gastric Acid Secretion in Dogs," JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 51, no. 4, pp. 457-464, April 1999.
PS	HOWDEN et al., "Appropriate Acid Suppression for Optimal Healing of Duodenal Ulcer and Gastro-Oesophageal Reflux Disease", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 29, no. SUPPL. 201, pp. 79-82, 1994.
PS	WILKINSON et al., "Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy," ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 13, no. 9, pp. 1205-1209, 1999.
PS	HENDREL et al., "Morning or evening dosage of omeprazole for gastro-oesophageal reflux disease? ALIMENTARY PHARMACOLOGY & THERAPEUTICS, vol. 9, no. 6, p. 693-697, 1995.
PS	DE CAESTECKER, "Medical therapy for supraesophageal complications of gastroesophageal reflux," AMERICAN JOURNAL OF MEDICINE, vol. 103, no. 5, Part A, pp. 138S-143S, November, 24, 1997.
PS	CENGIA et al., "Nocturnal Chronic Cough and Gerd: Clinical Correlations and Significance of Abnormal Proximal Esophageal Reflux", GASTROENTEROLOGY, vol. 116, No. 4, Part 2, Page A134, April 1999.
PS	MAY et al., "Estraesophageal manifestations of reflux disease concerning the airways", VERDAUUNGSKRANKHEITEN, vol. 16, No. 6, pp. 267-270, November, 1998.
PS	WORTH et al., "Interrelationships between gastro-esophageal reflux and airway diseases-pathophysiology, diagnostic and therapeutic possibilities," ATEMWEGS- UND LUNGENKRANKHEITEN, vol. 20, No. 12, pp. 697-700, 1994.
PS	RODRIGUEZ-TELLEZ M. et al., "Posterior laryngitis: Effects of treatment with omeprazole along.", REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, vol. 94, no. 3, pp. 127-130, 2002.

Examiner Signature	Phyllis Spivack	Date Considered	6/19/07
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO & 1449B/PTO

**FIRST
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	Unassigned 10/531900
Filing Date	April 21, 2005
First Named Inventor	Francois Schutze et al.
Examiner Name	Unassigned
Attorney Docket Number	032013-120

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	P. Spwack 6/19/07

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/531,900
Filing Date	June 23, 2006
First Named Inventor	Francois Schutze et al.
Examiner Name	SPIVAACK
Attorney Docket No.	1032013-000120

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
PS	7,034,038		Cohen et al.	04-25-2006
PS	2006-0194832	A1	Cohen et al.	08-31-2006
PS	2006-0287284	A1	Schutze et al.	12-21-2006
PS	2006-0241136	A1	Schutze et al.	10-26-2006

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	U.S. Serial No. 10/561,844 "Monohydrated Sodium Salt of S-Tenatoprazole and the Use Thereof in Therapy", filed December 22, 2005, attorney docket no. 1032013-000133.

Examiner Signature

Paul H. Spivack

Date Considered

6/27/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.